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Background: Endoscopic submucosal dissection (ESD) has become widely accepted as a standard treatment for
gastric epithelial neoplasms. Antithrombotic agents are widely used to prevent thromboembolic disease. However,
the feasibility of endoscopic procedures for patients using such agents has been rarely investigated. The aim of this
study was to identify risk factors for post-operative bleeding after gastric ESD and to evaluate the relationship
between the use of antithrombotic agents and post-operative bleeding.
Methods: From June 2005 to March 2014, 413 patients with 425 gastric neoplasms were treated by ESD. The
demographic and clinical parameters associated with post-operative bleeding were investigated. 83 patients
receiving antithrombotic agents were separately assessed using various methods of administration during the ESD
procedure. Post-operative bleeding that occurred within 5 days of ESD was defined as early post-operative bleeding,
whereas subsequent bleeding was defined as delayed bleeding.
Results: The overall post-operative bleeding rate was 4.7%. In patients with continued low-dose aspirin (LDA),
heparin replacement (HR), or continued LDA along with HR, post-operative bleeding rates were 9.5%, 23.8%, and
25.0%, respectively. On multivariate analysis, a specimen size of ≥40 mm was a risk factor for early post-operative
bleeding [odds ratio (OR) 6.08, 95% CI: 1.74–21.27], and HR and chronic kidney disease (CKD) requiring hemodialysis
were risk factors for delayed bleeding (OR 12.23, 95% CI: 2.63–56.77 and OR 28.35, 95% CI: 4.67–172.11, respectively).
Continued LDA was not a risk factor for post-operative bleeding.
Conclusions: Large specimen size is a risk factor for early post-operative bleeding, and HR and CKD requiring
hemodialysis are risk factors for delayed bleeding. Patients with risk factors should be carefully watched, allowing
for the timing of post-operative bleeding after ESD.
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Endoscopic submucosal dissection (ESD) is widely recog-
nized as the optimal treatment for gastric epithelial neo-
plasms [1-4]. The safety of gastric ESD has been mostly
established; however, post-operative bleeding is still the
main complication affecting the outcome of the procedure.
Antithrombotic agents are widely used to prevent
thromboembolic disease. The number of patients tak-
ing antithrombotic agents has increased as a result of
increases in the incidence of ischemic heart disease,
cerebrovascular disease, and arteriosclerosis obliterans.
Although antithrombotic agents are very effective in the
management of thromboembolic diseases [5,6], their use
increases the incidence of gastrointestinal (GI) bleeding
[7-9]. MacQuaid et al. found that low-dose aspirin (LDA)
increases the risk of major GI bleeding (relative risk 2.07,
95% CI: 1.61–2.66) in meta-analysis [8]. In addition, Lanas
et al. reported that Helicobacter pylori infection increased
the risk of upper GI bleeding in patients taking LDA
[10]. On the other hand, endoscopic procedures such as
ESD cause post-operative bleeding at a constant rate.
Previous studies have reported that the post-operative
bleeding rate was approximately 5% after gastric ESD
[11-14]. Because many patients who undergo gastric
ESD are infected with Helicobacter pylori, the post-ESD
bleeding rate for patients receiving antithrombotic
agents is expected to be >5%.
In clinical practice, healthcare workers need to balance
the risks of hemorrhage after endoscopic procedures
and thromboembolic events after medication cessation.
The American Society for Gastrointestinal Endoscopy
(ASGE) guidelines for the management of antithrom-
botic agents for endoscopic procedures recommend the
continued use of LDA for GI endoscopies, even for proce-
dures with a high risk of hemorrhage [15]. In contrast, the
European Society of Gastrointestinal Endoscopy (ESGE)
guidelines recommend that LDA should be continued for
most endoscopies, but discontinued for 5 days prior to
ESD and other procedures with a high risk of hemorrhagic
complications, provided the risk of thromboembolic
events is low [16]. Guidelines for the management of anti-
coagulant and antiplatelet therapy in patients undergoing
endoscopy were published in Japan in 2012 [17,18]. The
Japanese guidelines recommend endoscopic procedures
without interruption of LDA therapy in patients at high
risk of thromboembolic events who use LDA alone. On
the other hand, it is recommended that anticoagulants,
such as warfarin, can be replaced by heparin as a bridge
therapy [17,18]. However, there is insufficient data to
support these strategies. Furthermore, the risk of bleeding
after gastric ESD for patients routinely using LDA remains
controversial [19,20]. The aim of the present study
was to identify risk factors for post-operative bleeding
and to evaluate the relationship between the use ofantithrombotic agents and post-operative bleeding in
patients who underwent ESD for gastric neoplasms.
Methods
Patients
This was a retrospective study. A total of 425 gastric epi-
thelial neoplasms (412 early gastric cancers and 13 gastric
adenomas) in 413 patients were treated with ESD at the
Chiba University Hospital (Japan) from June 2005 to
March 2014. Of the 413 patients, 83 (20.0%) were on anti-
thrombotic therapy (warfarin potassium in 21 patients,
antiplatelet drugs in 62 patients, both warfarin potassium
and antiplatelet drugs in 4 patients, and two kinds of anti-
platelet drug in 7 patients). All 83 patients were classified
into one of two groups, at higher- or lower-risk of
thromboembolism, according to risk stratifications based
on published criteria [17,18]. The high risk of thrombo-
embolism was defined based on the following: two months
following coronary artery bare metal stenting; twelve
months following coronary artery drug eluting stenting;
two months following carotid arterial revascularization
(carotid endarterectomy or stenting); ischemic stroke or
transient ischemic attack with >50% stenosis of major
intracranial arteries; recent ischemic stroke or transient
ischemic attack; obstructive peripheral artery disease ≥
Fontaine grade 3 (rest pain); ultrasonic examination of
carotid arteries and magnetic resonance angiography of
the head and neck region where withdrawal is considered
high risk of thromboembolism; history of cardiogenic
brain embolism; atrial fibrillation accompanying valvular
heart disease; atrial fibrillation without valvular heart
disease but with a high risk of stroke; following mechan-
ical mitral valve replacement; history of thromboembolism
following mechanical valve replacement; antiphospholipid
antibody syndrome; and deep vein thrombosis/pulmonary
thromboembolism [17,18]. Of the 46 high-risk patients,
21 continued LDA during the procedures, 21 underwent
intravenous heparin replacement (HR), and 4 patients
continued LDA and underwent HR. In the 37 low-risk
patients, antithrombotic agents were temporarily stopped
before the procedures and restarted within 5 days of the
procedures (day 1, 3, and 5 after procedures in 26, 2, and
9 patients, respectively).
The indications for ESD were determined on the basis
of endoscopic findings, including chromoendoscopy
with indigo carmine dye, and biopsy. We referred to the
criteria described by Gotoda et al. [1] for possible node-
negative gastric epithelial neoplasia.
ESD procedure
ESD was performed with a conventional single-channel
endoscope (GIF-H260Z or -Q260J; Olympus, Tokyo, Japan)
or a two-channel endoscope (2TQ260 M; Olympus).
We mainly used an IT knife 2 (KD-611 L; Olympus),
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gical generator (VIO 300D; ERBE, T¨ubingen, Germany).
In addition, we used other electrosurgical knives as
necessary, including an IT knife (KD-610 L or KD-
611 L; Olympus), a Hook knife (KD-620LR; Olympus),
or a Flush knife (DK-2618; Fujifilm Inc., Tokyo, Japan),
with an ICC200 (ERBE) electrosurgical generator. The
injection solutions contained glycerin and hyaluronic
acid sodium (0.4%) with 1% indigo carmine dye. The
ulcers that developed after ESD were endoscopically
examined and any visible vessels were heat-coagulated
using hemostatic forceps (FD-410LR; Olympus). The
resected specimens were stretched, pinned flat on a
corkboard, and measured.
Management after ESD
Beginning on the day of ESD, omeprazole (40 mg/day)
was administered intravenously. From June 2005 to
September 2013, we performed second-look endoscopies
the day after ESD and coagulated all exposed vessels on
artificial ulcers, regardless of whether or not bleeding was
present. After October 2013, we did not routinely perform
second-look endoscopies. We also checked hemoglobin
levels the morning after ESD. If no ESD-related complica-
tions occurred, patients were allowed to have a liquid diet.
From 2 days after ESD, all patients received 20-mg omep-
razole or esomeprazole, and sodium alginate (120 ml/day)
orally. Patients were discharged the day after a diet was
established. After discharge, patients were instructed to
take 20-mg omeprazole or esomeprazole once a day for
28 days.
Management of patients taking anticoagulants
When gastric ESD was performed in patients receiving
oral anticoagulants such as warfarin, anticoagulants were
stopped temporarily 3 days before the procedure and
HR was used as a bridge therapy. Unfractionated heparin
was used for HR. A continuous administration of heparin
was initiated and controlled to keep the activated partial
thromboplastin time (APTT) at approximately 60 s. Intra-
venous HR was stopped 6 h before ESD. In addition, the
prothrombin time international normalized ratio (PT-INR)
was measured before ESD to confirm that the drug
effect had disappeared. After ESD, intravenous HR was
restarted 2 h after the procedure and oral anticoagu-
lants were restarted the next day after the procedure.
Heparin sodium was discontinued when the PT-INR
level had reached approximately 1.50.
Post-operative bleeding
Post-operative bleeding was defined as a decrease in the
blood hemoglobin level of >2 g/dL accompanied by an
occurrence of hematemesis, melena, or a combination of
unstable vital signs within 4 weeks of ESD. The typicalperiod of hospitalization after ESD was 5 days. There-
fore, post-operative bleeding that occurred within 5 days
of ESD was defined as early post-operative bleeding, and
subsequent bleeding was defined as delayed post-operative
bleeding. All patients with post-operative bleeding under-
went emergency esophagogastroduodenoscopy (EGD).
Information was recorded regarding the time of bleeding
and whether any interventions were performed.
Histopathological examination and curability after ESD
Histopathological examination was based on the 2010
Japanese Classification of Gastric Carcinoma issued by the
Japanese Gastric Cancer Association (JGCA) [21]. The
entire resected specimen was cut into parallel 2-mm
sections and examined with hematoxylin and eosin
staining for detailed analysis, including the analysis of
the deepest portion containing infiltrating cancer cells.
Gastric carcinomas were classified as differentiated or un-
differentiated. The former type included well-differentiated
tubular adenocarcinoma, moderately differentiated tubular
adenocarcinoma, and papillary adenocarcinoma. The
latter type included poorly differentiated adenocarcin-
oma, signet ring cell carcinoma, and mucinous adeno-
carcinoma. En bloc resection was defined as resection in
a single piece. Complete resection was defined as an
en bloc resection of a tumor that was shown to be free
of cancer cells at both the horizontal and vertical cut
ends. The resection was judged as curative when all the
following criteria were met: en bloc removal, tumor
size ≤ 2 cm, differentiated type, pT1a, negative horizon-
tal margin (HM0), negative vertical margin (VM0), and
no lymphovascular infiltration [ly (−), v (−)]. Curative
resection for early gastric carcinomas that fell under the
expanded indications was defined as follows: en bloc
resection, HM0, VM0, ly (−), and v (−) as well as (1)
tumor size > 2 cm, differentiated type, pT1a, and ulcer-
ation (UL) −; (2) tumor size ≤ 3 cm, differentiated type,
pT1a, and UL +; (3) tumor size ≤ 2 cm, undifferentiated
type, pT1a, and UL −; or (4) tumor size ≤ 3 cm, differen-
tiated type, and pT1b (SM1, ≤0.5 mm from the muscu-
laris mucosae) [22].
Statistical analysis
Some of the patients had more than one gastric neo-
plasm, and therefore underwent more than one ESD
procedure. For statistical purposes, the data from mul-
tiple ESD-induced ulcers occurring in certain patients
were assumed to constitute independent observations.
Baseline data are presented as mean ± SD. Differences
in clinical parameter values between groups were ana-
lyzed by unpaired t-tests or chi-square tests. The post-
operative bleeding rate was established, and the factors
associated with post-operative bleeding were assessed
using univariate and multivariate analyses. Variables
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into multivariate logistic regression analysis. All statis-
tical analyses were performed using SPSS 20.0 (SPSS
Inc., Chicago, IL, USA). A P-value of <0.05 was consid-
ered statistically significant.
Ethics considerations
Informed consent was obtained from all patients. The
study was conducted in accordance with the Declaration
of Helsinki (1995) after the protocol had been approved
by the institutional review board of the Chiba University
School of Medicine. In addition, this study was regis-




Clinical outcomes are shown in Table 1. The complete
en bloc resection rate was 95.1%, perforation rate was
0.5%, and overall post-operative bleeding rate was 4.7%.
The clinical characteristics of gastric lesions in patients
with gastric neoplasms are shown in Table 2.
Post-operative bleeding
Twenty patients (4.7%) had post-operative bleeding.
Table 2 shows clinical differences between patients with
post-operative bleeding and those without. In patients
with continued LDA, HR, or continued LDA and HR,
the post-operative bleeding rates were 9.5%, 23.8%, and
25.0%, respectively. In patients with chronic kidney dis-
ease (CKD) requiring hemodialysis, the post-operative
bleeding rate was 20%. Among all patients with post-
operative bleeding patients with HR and CKD requiring
hemodialysis were significantly more likely to bleed
than those without post-operative bleeding (P < 0.05).
In addition, the maximum diameter of the tumor was
significantly larger in patients with post-operative bleeding
than those without post-operative bleeding (P < 0.05). All
the post-operative bleeding occurred within 10 days of
ESD. Early and delayed post-operative bleeding oc-
curred in 11 and 9 patients, respectively. In 3 patients,Table 1 Clinical outcomes of ESD
Characteristic
Complete en bloc resection (%) 95.1
Curability
Curative resection (%) 72.3
Expanded curative resection (%) 21.4
Non-curative resection (%) 6.3
Complication
Perforation (%) 0.5
Post-operative bleeding (%) 4.7we confirmed post-operative bleeding on second-look
endoscopy, and two of them were patients taking anti-
thrombotic agents.
Factors associated with post-operative bleeding
Table 3 shows univariate and multivariate analyses of the
risk factors associated with overall post-operative bleed-
ing. These analyses revealed that HR, CKD requiring
hemodialysis, and a maximum specimen diameter of
≥40 mm were risk factors for post-operative bleeding
[odds ratio (OR) 5.77, 95% CI: 1.67–19.96; OR 33.86,
95% CI: 4.72–242.74; and OR 3.70, 95% CI: 1.09–12.52,
respectively]. We repeated the univariate analysis, chan-
ging the threshold for specimen size from 30 to 50 mm
in 10 mm increments. We determined the threshold
when the probability value was the lowest and found a
specimen size threshold of 40 mm. The maximum diam-
eter of tumor size was strongly correlated to specimen
size (Pearson product moment correlation, r = 0.68, P <
0.05). Therefore, tumor size was excluded from this ana-
lysis. The relationship between risk factors and the time
of post-operative bleeding is shown in Figure 1. Table 4
shows the univariate analysis of the risk factors associ-
ated with early post-operative bleeding. This analysis
revealed that a specimen size of ≥40 mm was a risk
factor for early post-operative bleeding (OR 6.08, 95%
CI: 1.74–21.27). In contrast, Table 5 shows the univariate
and multivariate analyses of the risk factors associated
with delayed post-operative bleeding. These analyses
revealed that HR and CKD requiring hemodialysis were
risk factors for delayed post-operative bleeding (OR 12.23,
95% CI: 2.63–56.77 and OR 28.35, 95% CI: 4.67–172.11,
respectively). The post-operative bleeding rate was higher
in patients with continued LDA. However, there was no
statistical association between post-operative bleeding and
continued LDA.
Management of post-operative bleeding
All patients with post-operative bleeding underwent
emergency EGD and endoscopic treatment and recov-
ered completely after endoscopic and medical treatment.
Discussion
In previous guidelines, the cessation of antithrombotic
agents during endoscopic procedures was recommended
because the emphasis was on the prevention of GI
bleeding. However, recently the risks associated with the
cessation of such agents have been widely reported
[23-26]. Therefore, the management of antithrombotic
agents during endoscopic procedures has changed. In
Japan, the guidelines were revised in 2012, and endo-
scopic procedures can be performed without the inter-
ruption of LDA therapy in patients at high risk for
thromboembolic events [17,18]. However, no consensus








Sex (male/female) 302/123 18/2 284/121 n. s.*
Age (years, mean ± SD) 72.1 ± 8.6 71.9 ± 10.0 72.1 ± 8.5 n. s.**
Tumor location (n, %)
Upper 65 (15) 3 (15) 62 (15) n. s.*
Middle 179 (42) 6 (30) 173 (43) n. s.*
Lower 181 (43) 11 (55) 170 (42) n. s.*
Tumor size (mm, mean ± SD) 18.4 ± 12.6 29.6 ± 21.8 17.8 ± 11.7 <0.05**
Specimen size (mm, mean ± SD) 33.9 ± 13.3 41.3 ± 17.6 33.6 ± 12.9 0.07**
Invasion depth
M 396 18 378 n. s.*
SM1 15 1 14 n. s.*
SM2 14 1 13 n. s.*
Ulceration (+/-) 418/7 19/1 399/6 n. s.*
Medication used (n, %)
Continued use of LDA 21 (9) 2 (10) 19 (5) n. s.*
Continued use of LDA + heparin replacement 4 (1) 1 (5) 3 (0.7) n. s.*
Heparin replacement 21 (5) 5 (25) 16 (4) <0.05*
Cessation of antithrombotic agent during ESD procedure 41 (9) 2 (10) 39 (10) n. s.*
Comorbidity (n, %)
Liver cirrhosis 20 (5) 2 (10) 18 (4) n. s.*
CKD undergoing hemodialysis 20 (5) 4 (20) 16 (4) <0.05*
Second-look endoscopy (+/-) 356/69 19/1 337/68 n. s.*
LDA: Low-dose aspirin.
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the use of these agents is a risk factor for post-operative
bleeding after ESD. In previous studies, Koh et al. and
Takeuchi et al. reported that the use of antithrombotic
drugs was a risk factor for post-operative bleeding after
ESD [27,28]. However, in these reports, antithrombotic
drug therapies were interrupted preoperatively in all
patients. In this regard, these studies differed from our
research that focused on the continued use of anti-
thrombotic agents and risk factors for post-operative
bleeding. On the other hand, Cho et al. also reported an
increased risk of bleeding after gastric ESD in a recent
study of 19 patients with the continued use of LDA [19].
In contrast, Sanomura et al. reported that the continued
use of LDA did not increase the risk of bleeding during
or after ESD in 25 patients with the continued use of
LDA [20]. In our study, we studied 83 patients and used
various methods for administering antithrombotic agents.
Our study included 25 patients with the continued use of
LDA. The continued use of LDA was not a risk factor
but HR, CKD requiring hemodialysis, and a maximumspecimen diameter of ≥40 mm were risk factors for
post-operative bleeding. In addition, in our study, we
evaluated the relationship between risk factors and the
time of post-operative bleeding. Large specimen size
was a risk factor for early post-operative bleeding, and
HR and CKD requiring hemodialysis were risk factors
for delayed bleeding. A temporary cessation of anti-
thrombotic agents during the ESD procedure was not a
risk factor for post-operative bleeding.
In previous studies, Kakushima et al. reported that ESD-
induced gastric ulcers healed within 8 weeks, regardless of
the size and location, and fibrosis and wall thickening were
observed from 2 weeks after ESD [29,30]. In addition,
Goto et al. reported that visible vessels, which occurred in
approximately one quarter of the ulcers within 3 days of
ESD, were rarely observed 4 days after ESD [31]. Consid-
ering these studies and our results, these visible vessels
may cause early post-operative bleeding and may depend
on the size of ESD-induced ulcers. In contrast, delayed
bleeding may be caused by the delayed healing of ulcers,
which in turn may be caused by HR and CKD requiring
Table 3 Univariate and multivariate analyses of risk factors associated with overall post-operative bleeding
Univariate analysis Multivariate analysis
Risk factor OR (95% CI) p-value OR (95% CI) p-value
Male gender (vs. Female) 3.91 (0.89-17.11) 0.07* 6.40 (0.69-58.69) 0.10
Age ≥70 years (vs. ≤69 years) 1.01 (0.39-2.58) 0.99
Tumor location Lower (vs. Upper and Middle) 1.65 (0.67-4.08) 0.27
Continued use of LDA 2.97 (0.81-10.92) 0.10
Continued use of LDA + heparin replacement 6.84 (0.68-68.89) 0.10
Heparin replacement 7.99 (2.77-22.99) <0.01* 5.77 (1.67-19.96) 0.01*
Cessation of antithrombotic agent during ESD procedure (vs. No antithrombotic therapy) 1.82 (0.38-8.68) 0.45
Liver cirrhosis 1.51 (0.33-6.83) 0.59
CKD undergoing hemodialysis 19.40 (4.75-79.19) <0.01* 33.86 (4.72-242.74) <0.01*
Specimen size ≥40 mm (vs. < 40 mm) 2.84 (1.14-7.09) 0.03* 3.70 (1.09-12.52) 0.04*
Procedure time ≥90 min (vs. < 90 min) 3.05 (1.12-8.29) 0.03* 2.45 (0.74-8.16) 0.15




CKD: Chronic kidney disease.
*p<0.05.
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under HR was associated with a high risk of post-
operative bleeding (37.5%), a finding that was similar to
the result in our study (23.8%) [32]. These high inci-
dences of post-operative bleeding may be caused using
two kinds of anticoagulant therapy (oral anticoagulants
and intravenous heparin) from the day after ESD. WeFigure 1 The relationship between the time of post-ESD bleeding and
with specimen size ≥ 40 mm occurred within 5 days of ESD. On the ot
or more risk factors occurred after 6 days after ESD.routinely performed second-look endoscopy before
September 2013. However, in a prospective, random-
ized, controlled study, Ryu et al. found that second-look
endoscopy was not associated with clinical outcomes
including bleeding and morbidity after gastric ESD [33].
For this reason, we did not perform second-look endos-
copy routinely after October 2013. In the present study,risk factors: most cases of post-operative bleeding in patients
her hand, most cases of post-operative bleeding in patients with one
Table 4 Univariate and multivariate analyses of risk factors associated with early post-operative bleeding
Univariate analysis Multivariate analysis
Risk factor OR (95% CI) p-value OR (95% CI) p-value
Male gender (vs. Female) 4.25 (0.53-33.61) 0.17
Age ≥70 years (vs. ≤69 years) 1.45 (0.38-5.57) 0.58
Tumor location Lower (vs. Upper and Middle) 2.36 (0.68-8.20) 0.17
Continued use of LDA 3.66 (0.74-17.93) 0.11
Continued use of LDA + heparin replacement 13.30 (1.27-139.25) 0.03* 32.88 (2.61-414.05) <0.01*
Heparin replacement 3.50 (0.71-17.10) 0.12
Cessation of antithrombotic agent during ESD procedure (vs. No antithrombotic therapy) 3.08 (0.60-15.87) 0.18
Liver cirrhosis 1.33 (0.16-10.81) 0.78
CKD undergoing hemodialysis 4.92 (0.56-43.20) 0.15
Specimen size ≥40 mm (vs. < 40 mm) 6.08 (1.74-21.27) <0.01* 8.03 (2.03-31.72) <0.01*
Procedure time ≥90 min (vs. < 90 min) 3.44 (0.81-14.71) 0.10




CKD: Chronic kidney disease.
*p<0.05.
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endoscopy and post-operative bleeding. There was no
statistical association between post-operative bleeding
and second-look endoscopy.
There are several limitations to this study. First, the
study was a retrospective study and was conducted at a
single center. Second, this study contained a small number
of cases with the continued use of antithrombotic agents.
Third, the number of patients with post-operative bleedingTable 5 Univariate and multivariate analyses of risk factors a
Risk factor
Male gender (vs. Female)
Age ≥70 years (vs. ≤69 years)
Tumor location Lower (vs. Upper and Middle)
Continued use of LDA
Continued use of LDA + heparin replacement
Heparin replacement
Cessation of antithrombotic agent during ESD procedure (vs. No antithromb
Liver cirrhosis
CKD undergoing hemodialysis
Specimen size ≥40 mm (vs. < 40 mm)
Procedure time ≥90 min (vs. < 90 min)




CKD: Chronic kidney disease.
N/A: Not applicable.
*p<0.05.was small. These limitations indicate that our study
requires further validation. In addition, the cessation
of antithrombotic agents in patients at high risk of
thromboembolism is difficult in view of the risks asso-
ciated with the cessation of such agents. Therefore, we
could not perform a randomized controlled study that
stratified patients on the basis of the risk of thrombo-
embolism. In the future, further research involving
large numbers of patients is warranted.ssociated with delayed post-Operative bleeding
Univariate analysis Multivariate analysis






13.89 (3.48-55.39) <0.01* 12.23 (2.63-56.77) <0.01*
otic therapy) N/A N/A
1.67 (0.20-13.9) 0.63
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Large specimen size is a risk factor for early post-operative
bleeding, and HR and CKD requiring hemodialysis are risk
factors for delayed bleeding. In contrast, continued LDA is
not a risk factor for post-operative bleeding. Patients with
risk factors should be carefully watched, allowing for the
timing of post-operative bleeding after ESD.
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